Loading…
Based on limited metadata, this FDA Warning Letter issued to Dexcowin Co. Ltd. on February 20, 2018, involves a company with an unspecified product type classified as "Other." Without access to the full letter text or a detailed subject line, the specific nature of the regulatory violations cannot be determined from the available information. The issuing office is also not identified in the metadata, which limits clarity on the regulatory scope and product category involved. To understand the company's compliance issues and the FDA's specific concerns, the complete warning letter would need to be reviewed.